asianprimenews
Breaking News
Breaking NewsGeneralPublic Interest

Divya Khossla’s Savi Completes 1 Year! A Film That Marked Her Powerful Transformation On-Screen

by asianprimenews0378

Exactly one year ago, Divya Khossla starred in Savi and delivered a film that marked her powerful transformation on screen. Today, the film completes one year since its official release, and Divya is excited to celebrate a project that threw light on her acting range, intensity, and sheer grit. Directed by Abhinay Deo, the film saw Divya as a housewife who refuses to give up after her husband is wrongly accused of his boss’s murder.

As Savi completes one year today, Divya Khossla reflects back on how it resonated with the audience, received critical acclaim, and established her as an actress who carries more determination than what meets the eye. “Savi is a film that’s very dear to me, and it will always be a special one. It just felt like yesterday when we were filming with Harshvardhan Rane, Anil Kapoor and our director Abhinay Deo. Though it was challenging to play Savi, I knew I had to do this role and throw light on a wife’s ferocious side to go above and beyond for her husband,” says Divya.

She adds, “There couldn’t have been a bigger validation for me than picking a character that connected with the viewers, added to the film’s commercial success, and I’m glad that I chose this project.”

Divya celebrated the feat by sharing a few BTS stills from the sets, and also penned a note that read, ““She moved mountains for L❤️VE “ #1yearofSavi & working with the Best Team ever ❤️Can’t thank Mukesh Bhatt sir & Abhinay Deo ji enough & Can’t thank you all enough for so much love u gave to #SAVi 🙏❤️ Also can’t wait to share with you all my next after Savi 😇🤞🏻”

https://www.instagram.com/p/DKTnrs8qu1G/?igsh=MWI5bDM3dmg2MGR1cw%3D%3D&img_index=2

Divya Khossla’s intriguing performance in Savi kept the audience glued to the screens with emotional sequences, witty dialogues, and a riveting climax. While the film kept the audience on the edge of their seats, Divya Khossla surprised the viewers by stepping into uncharted territory, something that the viewers hadn’t predicted. By playing the main character, she not only boosted the film’s profitable affair, but also registered a strong title to her body of work.

Now, Divya Khossla is working with director Prerna Arora on an upcoming project. Currently untitled, their collaboration has raised excitement among audiences who are eager to see what they have in the store. The details of the project are yet to be unveiled, and an official announcement is yet to be made.

Share

Related posts

HCCB to implement community projects in 14 villages including upskilling 5,500 people in Maharashtra

asianprimenews

Why CML Isn’t a Solved Disease—And What Patients in India Need to Know* Over the past two decades, Chronic Myeloid Leukemia (CML) has undergone a transformation—from being a life-threatening condition to one that can be controlled with oral medication. Although survival rates have improved significantly, the idea of CML as a ‘manageable’ disease is now being questioned. Clinicians and patients alike are recognizing that the existing standard of care does not address the full picture—especially for India’s younger patient population, whose needs go far beyond survival. Dr Subhaprakash Sanyal Director of Haematology and BMT Services, Fortis Hospital, Mumbai, said, “There’s a common belief that starting treatment for CML means the journey is simple, but that isn’t the case. Many patients struggle to reach their treatment milestones as expected, and a significant portion need to change or stop their medication due to side effects or intolerance. In fact, about 30 to 40% discontinue their initial therapy within five years, highlighting that the standard approach doesn’t work for everyone.” CML disproportionately affects younger adults in India, where the median age of diagnosis is between 35 and 40 years—much younger than the average age of 50–60 in Western countries. At this life stage, patients are often building careers, supporting families, and planning long-term futures. In this context, treatment is no longer just about survival—it’s about maintaining energy, emotional well-being, professional productivity, and daily independence. Historically, the primary treatment goal in CML was achieving Major Molecular Response (MMR). But over the years, these goals have evolved. Today, physicians aim for deeper responses, particularly Deep Molecular Response (DMR). Achieving DMR paves the way for Treatment-Free Remission (TFR), where patients can potentially stop therapy altogether and remain in remission under medical supervision. These advanced milestones are particularly relevant to newly diagnosed patients, as reaching DMR within the first two years greatly improves the likelihood of achieving TFR down the line. Why So Many Patients Fall Short Despite clear treatment goals, a significant proportion fail to achieve MMR within the first year, and even fewer reach DMR by year two. One of the primary reasons is the impact of persistent, low-grade side effects—such as fatigue, joint pain, and gastrointestinal issues—which patients often tolerate silently but which meaningfully reduce their quality of life. These side effects also drive nonadherence, dose modifications, and ultimately treatment discontinuation. In fact, treatment intolerance is the leading cause of therapy discontinuation in the first two years of CML management. Adding to the complexity, current treatments—particularly ATP-competitive tyrosine kinase inhibitors (TKIs)—can affect not just the intended target but also unrelated biological pathways, causing off-target toxicity. This often leads to therapy switches, a strategy that increases both clinical and emotional burden without necessarily resolving the issue. A recent Indian analysis noted that nearly all CML patients report some form of low-grade side effect, many of which disrupt work and personal life but don’t qualify for hospitalization. As a result, patients feel caught in a difficult balance—managing a chronic illness while enduring ongoing discomfort or disruptions. The Case for Better-Tolerated, More Effective Therapies As the treatment landscape evolves, the need for therapies that not only offer deeper molecular responses but also better tolerability is becoming increasingly clear. Emerging therapies with novel mechanisms of action have begun to change the paradigm by offering comparable—or even superior—efficacy alongside fewer adverse events and lower discontinuation rates. In one international phase III trial, a newer therapy demonstrated a 74.1% MMR rate at 96 weeks, significantly higher than the 52.0% achieved by older therapies. It also showed a 54% lower risk of treatment discontinuation due to side effects, while nearly half of patients achieved MR4 and 30.9% achieved MR4.5, the deepest levels of response. These findings suggest that treatment no longer needs to be a trade-off between efficacy and day-to-day functioning. This shift is particularly important in the Indian context, where younger patients face the possibility of decades-long treatment. For them, the ability to tolerate therapy comfortably while still achieving long-term disease control is not a luxury—it’s a necessity. The Importance of Proactive Conversations Many patients continue older treatments unaware that newer, more tolerable options exist. This makes open doctor–patient conversations crucial—especially early in treatment. Patients should understand their goals, like DMR or TFR, and how their therapy aligns with them. Discussing side effects, lifestyle impact, and alternatives helps ensure care is not just effective, but sustainable and suited to their lives. While CML outcomes have improved, challenges remain—particularly for India’s younger patients. As treatment goals expand and better options emerge, the focus must shift from merely managing the disease to helping patients live well. The future of CML care lies in deeper responses, better tolerability, and enabling life beyond medication.

asianprimenews

Radico Khaitan brings ‘Jaisalmer Indian Craft Gin’ to Gin Explorers Club RetroverseEdition Mumbai

asianprimenews